Print Page     Close Window     

SEC Filings

10-K/A
BIOTIME INC filed this Form 10-K/A on 03/29/2017
Entire Document
 

ASTERIAS BIOTHERAPEUTICS, INC.
STATEMENTS OF OPERATIONS
(IN THOUSANDS, EXCEPT PER SHARE DATA)

   
Year Ended December 31,
 
   
2016
   
2015
   
2014
 
REVENUES:
                 
Grant income
 
$
6,572
   
$
3,007
   
$
1,035
 
Sale of cell lines
   
-
     
40
     
-
 
License revenue
   
125
     
-
     
-
 
Royalties from product sales
   
257
     
535
     
189
 
Total revenues
   
6,954
     
3,582
     
1,224
 
 
                       
Cost of sales
   
(128
)
   
(268
)
   
(95
)
 
                       
Total gross profit
   
6,826
     
3,314
     
1,129
 
                         
OPERATING EXPENSES:
                       
Research and development
   
(25,467
)
   
(17,321
)
   
(13,310
)
General and administrative
   
(15,482
)
   
(7,901
)
   
(5,280
)
Total operating expenses
   
(40,949
)
   
(25,222
)
   
(18,590
)
 
                       
Loss from operations
   
(34,123
)
   
(21,908
)
   
(17,461
)
                         
OTHER INCOME/(EXPENSES):
                       
Loss from change in fair value of warrant liability
   
(3,108
)
   
-
     
-
 
Interest expense, net
   
(546
)
   
(341
)
   
(10
)
Other expense, net
   
(37
)
   
(6
)
   
(2
)
Total other expenses, net
   
(3,691
)
   
(347
)
   
(12
)
                         
LOSS BEFORE INCOME TAX BENEFIT
   
(37,814
)
   
(22,255
)
   
(17,473
)
                         
Deferred income tax benefit
   
2,325
     
7,252
     
7,376
 
                         
NET LOSS
 
$
(35,489
)
 
$
(15,003
)
 
$
(10,097
)
                         
BASIC AND DILUTED NET LOSS PER SHARE
 
$
(0.83
)
 
$
(0.42
)
 
$
(0.33
)
WEIGHTED AVERAGE SHARES OUTSTANDING: BASIC AND DILUTED
   
42,934
     
35,443
     
30,720
 

The accompanying notes are an integral part of these financial statements.
 
46

© Copyright BioTime, Inc.